EU/3/14/1378

About

In September 2019, New B Innovation Biopharmaceutical (Ireland) Limited changed name to New Beta Innovation Biopharmaceutical (Ireland) Limited.

On 19 November 2014, orphan designation (EU/3/14/1378) was granted by the European Commission to New B Innovation (UK) Limited, United Kingdom, for diaspirin cross-linked haemoglobin for the treatment of hepatocellular carcinoma.

The sponsorship was transferred to New B Innovation Biopharmaceutical (Ireland) Limited, Ireland, in April 2019.

Key facts

Active substance
Diaspirin cross-linked haemoglobin
Disease / condition
Treatment of hepatocellular carcinoma
Date of first decision
19/11/2014
Outcome
Positive
EU designation number
EU/3/14/1378

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

New Beta Innovation Biopharmaceutical (Ireland) Limited
The Black Church
St. Mary's Place
Dublin
D07 P4AX
Ireland
Tel. +353 1 6461625
E-mail: priscilla.chan@newbinnovation.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating